Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lilly Invests $100 Million in China Animal Healthcare Ltd.

publication date: Apr 10, 2013
Eli Lilly’s animal health division, Elanco, will make a $100 million investment into China Animal Healthcare Ltd. The capital, which will give Elanco a 20% stake in China Animal Health, will be used, in part, to de-list China Animal Health from the Singapore Stock Exchange. China Animal Health IPO’d in Singapore in 2007, and then instituted a secondary listing in Hong Kong in 2010. Elanco said the two companies have set up a framework for future collaborations. More details....

Stock Symbols:  (NYSE: LLY) (SG: CAL; HK: 940)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital